Watchlist Price Alert

Cidara Therapeutics Inc. (CDTX)

NASDAQ: CDTX · Real-Time Price · USD

18.71

-0.44 (-2.30%)

At close: May 09, 2025, 3:59 PM

18.63

-0.45%

After-hours: May 09, 2025, 04:05 PM EDT

-2.30% (1D)

Bid	18.3
Market Cap	234.81M
Revenue (ttm)	8.77M
Net Income (ttm)	-167.58M
EPS (ttm)	-26.82
PE Ratio (ttm)	-0.7
Forward PE	-1.86
Analyst	Strong Buy

Ask	19.2
Volume	56,332
Avg. Volume (20D)	137,618
Open	20.97
Previous Close	19.15
Day's Range	18.50 - 20.34
52-Week Range	10.14 - 28.42
Beta	0.86

About CDTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CDTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CDTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

5 months ago

+15.41%

Cidara Therapeutics shares are trading higher. The... Unlock content with Pro Subscription

News

4 days ago · seekingalpha.com

Cidara Therapeutics: Strong Buy On Imminent Data Readout For Lead Flu Candidate

We initiate coverage on Cidara Therapeutics with a Strong Buy rating due to its strategic pivot to antiviral CD388 and promising Phase 2b trial data. Rezafungin's successful approval and divestiture t...

1 week ago · zacks.com

Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice

Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · zacks.com

Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know

The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

2 months ago · seekingalpha.com

Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388...